Literature DB >> 28708787

Factors Contributing to the Low Survival Among Women With a Diagnosis of Invasive Cervical Cancer in Ghana.

Yvonne Nartey1, Philip C Hill, Kwabena Amo-Antwi, Kofi M Nyarko, Joel Yarney, Brian Cox.   

Abstract

: Cervical cancer is one of the most common cancers among women worldwide, and more than 85% of the disease occurs in low- and middle-income countries. Although it ranks as the most common cancer in Ghanaian women, there are no data available on cervical cancer survival.
METHODS: Information on women with a diagnosis of cervical cancer from 2010 to 2013 was collected from the Komfo Anokye and Korle-Bu Teaching Hospitals through review of paper-based and electronic medical records (including pathology records) at the oncology units and the departments of obstetrics and gynecology. Telephone interviews were conducted with patients and relatives to gather further information. Data were recorded using a standardized questionnaire and analyzed using summary statistics.
RESULTS: Information for 821 women was available for the survival analysis. Of these, 497 (60.5%) died during follow-up. At 3 years after diagnosis, survival was 39%. Survival was lowest in women with stage IV disease. Women with squamous cell carcinoma had a survival advantage over those with adenocarcinoma. Furthermore, women who received surgery, radiotherapy, and chemotherapy had better survival than did women with other forms of treatment.
CONCLUSIONS: In conclusion, cervical cancer survival is low in Ghana and is likely to be improved if a greater proportion of the disease is detected early. Improving knowledge of the disease for early diagnosis, reducing financial barriers, and greater organization of health care delivery are likely to improve survival from cervical cancer in Ghana.

Entities:  

Mesh:

Year:  2017        PMID: 28708787     DOI: 10.1097/IGC.0000000000001088

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  5 in total

1.  Health-related quality of life among cervical cancer survivors at a tertiary hospital in Ghana.

Authors:  Kwabena Amo-Antwi; Ramatu Agambire; Thomas O Konney; Samuel B Nguah; Edward T Dassah; Yvonne Nartey; Adu Appiah-Kubi; Augustine Tawiah; Elliot K Tannor; Amponsah Peprah; Mavis Bobie Ansah; Daniel Sam; Patrick K Akakpo; Frank Ankobea; Rex M Djokoto; Maame Y K Idun; Henry S Opare-Addo; Baafour K Opoku; Alexander T Odoi; Carolyn Johnston
Journal:  PLoS One       Date:  2022-06-03       Impact factor: 3.752

2.  Recommendations for cervical cancer prevention and control in Ghana: public education and human papillomavirus vaccination.

Authors:  Yvonne Nartey; Philip Hill; Kwabena Amo-Antwi; Richard Asmah; Kofi Nyarko; Joel Yarney; Nelson Damale; Brian Cox
Journal:  Ghana Med J       Date:  2018-06

3.  Characteristics of Women Diagnosed with Invasive Cervicalzzm321990Cancer in Ghana

Authors:  Yvonne Nartey; Philip C Hill; Kwabena Amo-Antwi; Kofi M Nyarko; Joel Yarney; Brian Cox
Journal:  Asian Pac J Cancer Prev       Date:  2018-02-26

4.  HIV status, age at cervical Cancer screening and cervical cytology outcomes in an opportunistic screening setting in Nigeria: a 10-year Cross sectional data analysis.

Authors:  Jonah Musa; Chad J Achenbach; Charlesnika T Evans; Neil Jordan; Patrick H Daru; Olugbenga Silas; Atiene S Sagay; Rose Anorlu; Supriya D Mehta; Firas Wehbe; Melissa A Simon; Isaac F Adewole; Lifang Hou; Robert L Murphy
Journal:  Infect Agent Cancer       Date:  2019-11-29       Impact factor: 2.965

5.  Comparison of Definitive Cervical Cancer Management With Chemotherapy and Radiation Between Two Centers With Variable Resources and Opportunities for Improved Treatment.

Authors:  Francis Adumata Asamoah; Joel Yarney; Aba Scott; Verna Vanderpuye; Zhigang Yuan; Daniel C Fernandez; Michael E Montejo; Mervin Agyeman; Samuel Ntiamoah Boateng; Kwabena Anarfi; Charles Aidoo; Mian M Shahzad; Jing-Yi Chern; Hye-Sook Chon; Robert M Wenham; Kosj Yamoah; Kamran A Ahmed
Journal:  JCO Glob Oncol       Date:  2020-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.